Released on = March 31, 2006, 8:34 am

Press Release Author = Kevin Nally

Industry = Biotech

Press Release Summary = Flemington, N.J. , March 31st, 2006 Zangani Investor
Community, an outsourced IR and Business Development firm specializing in small cap
and micro cap companies announced today that it interviewed Marc Canton, President
of ViRexx Medical Corporation (TSX:VIR; AMEX:REX), on March 23rd, 2006. Mr. Canton
discussed latest stage drug candidates for treatment of ovarian cancer and chronic
hepatitis B and C., as well as, the Company's latest growth strategies and its
listing on the AMEX.

Press Release Body = To access the interview, please visit the Zangani Investor
Community at:
www.zangani.com/virexx/2006-0323-rex .The interview is also available via Podcast at
www.zangani.com or through the itunes music store.

About ViRexx Medical Corp.

ViRexx is an Edmonton, Alberta based biotechnology company focused on the
development of novel therapeutic products for the treatment of certain cancers and
specified chronic viral infections. ViRexx\'s most advanced programs include drug
candidates for the treatment of ovarian cancer, chronic hepatitis B and C and solid
tumors.

ViRexx\'s lead product candidate, OvaRex® MAb, a therapy for the treatment of
late-stage ovarian cancer, is currently the subject of two Phase III clinical trials
being funded by ViRexx\'s licensing partner Unither Pharmaceuticals, Inc., a
subsidiary of United Therapeutics Corporation. For additional information about
ViRexx, please see www.virexx.com.

About Zangani
Zangani is an outsourced IR and Business Development firm specializing in small cap
and micro cap companies. They provide clients with an array of investor relations
products, including customized company strategies, community forums, and webcasting
which are tailored for small cap budgets. For more information please visit their
website at http://www.zangani.com

Note: Except for the historical information contained herein, this press release
contains, among other things, certain forward-looking statements, within the meaning
of the Private Securities Litigation Reform Act of 1995, that involve risks and
uncertainties. Such statement may include, without limitation, statements with
respect to the Company's plans, objectives, expectations and intentions and other
statements identified by words such as "may", "could", "would", "should",
"believes", "expects", "anticipates", "estimates", "intends", "plans" or similar
expressions. These statements are based upon the current beliefs and expectations
of the Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks and
uncertainties that are subject to change based on various factors (many of which are
beyond the Company's control).

L.G. Zangani, LLC provides financial public relations service to the Company. As
such L.G. Zangani, LLC and/or its officers, agents and employees, receives
remuneration for public relations and or other services in the form of monies,
capital stock in the Company, warrants or options to purchase capital in the
Company. The full disclaimer can be read here at http://www.zangani.com/disclaimer.

Contact:
Kevin Nally
Zangani Investor Community
9 Main Street
Flemington, NJ 08822
office@zangani.com
http://www.zangani.com


Web Site = http://www.zangani.com

Contact Details = Zangani
9 Main Street
Flemington, NJ 08822
office@zangani.com
908-788-9660 x625